Imatinib is able to target tyrosine kinase and decrease the synthesis of BCR/ABL fusion gene, Naito et al reported their experience of treating a patient with CML accompanied by EBC with imatinib and obtained favorable results (16). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.